NZ723750A - Compositions and methods for the treatment of her2/neu over-expressing tumors - Google Patents
Compositions and methods for the treatment of her2/neu over-expressing tumorsInfo
- Publication number
- NZ723750A NZ723750A NZ723750A NZ72375015A NZ723750A NZ 723750 A NZ723750 A NZ 723750A NZ 723750 A NZ723750 A NZ 723750A NZ 72375015 A NZ72375015 A NZ 72375015A NZ 723750 A NZ723750 A NZ 723750A
- Authority
- NZ
- New Zealand
- Prior art keywords
- recombinant
- her2
- listeria
- neu
- vaccine
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 title 1
- 241000186781 Listeria Species 0.000 abstract 6
- 229920001184 polypeptide Polymers 0.000 abstract 5
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 5
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 5
- 229960005486 vaccine Drugs 0.000 abstract 5
- 101150029707 ERBB2 gene Proteins 0.000 abstract 4
- 230000002238 attenuated effect Effects 0.000 abstract 3
- 108020004707 nucleic acids Proteins 0.000 abstract 3
- 102000039446 nucleic acids Human genes 0.000 abstract 3
- 150000007523 nucleic acids Chemical class 0.000 abstract 3
- 108090000790 Enzymes Proteins 0.000 abstract 2
- 102000004190 Enzymes Human genes 0.000 abstract 2
- 108700026244 Open Reading Frames Proteins 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 230000002503 metabolic effect Effects 0.000 abstract 2
- 201000008968 osteosarcoma Diseases 0.000 abstract 2
- 241000282465 Canis Species 0.000 abstract 1
- 239000003242 anti bacterial agent Substances 0.000 abstract 1
- 230000003115 biocidal effect Effects 0.000 abstract 1
- 210000000349 chromosome Anatomy 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000003550 marker Substances 0.000 abstract 1
- 206010061289 metastatic neoplasm Diseases 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
This invention provides compositions and methods for treating and vaccinating against a HER2/neu antigen-expressing tumor and inducing an immune response against the same in a subject. In a specific embodiment the invention is the use of a recombinant attenuated Listeria in the manufacture of a medicament for delaying or preventing metastatic disease in a subject with a HER2/neu-expressing osteosarcoma wherein said recombinant attenuated Listeria comprises a nucleic acid molecule encoding a recombinant polypeptide, wherein said recombinant polypeptide comprises a HER2/neu chimeric antigen fused to an additional polypeptide, wherein said nucleic acid molecule comprises a first open reading frame encoding said recombinant polypeptide, wherein said nucleic acid molecule further comprises a sec-ond open reading frame encoding a metabolic enzyme, and wherein said metabolic enzyme complements an endogenous gene that is mutated in the chromosome of said recombinant Listeria strain, wherein said recombinant attenuated Listeria is to be administered as an initial vaccine, and as a first booster vaccine between 5 and 10 months after said initial vaccine, and as a second booster vaccine between 4 and 15 months after said first booster vaccine. This system does not require the use of an antibiotic resistance marker to maintain the vector encoding the recombinant polypeptide in the Listeria. The recombinant at-tenuated Listeria may also be used in a method of treating canine HER2/neu-expressing osteosarcoma.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14/189,008 US20150366955A9 (en) | 2009-11-11 | 2014-02-25 | Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumors |
| US14/268,436 US20140234370A1 (en) | 2009-11-11 | 2014-05-02 | Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumors |
| US201462076411P | 2014-11-06 | 2014-11-06 | |
| PCT/US2015/017559 WO2015130810A2 (en) | 2014-02-25 | 2015-02-25 | Compositions and methods for the treatment of her2/neu over-expressing tumors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ723750A true NZ723750A (en) | 2024-02-23 |
Family
ID=54009773
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ723750A NZ723750A (en) | 2014-02-25 | 2015-02-25 | Compositions and methods for the treatment of her2/neu over-expressing tumors |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP3110942A4 (en) |
| JP (1) | JP2017507943A (en) |
| KR (2) | KR20240038103A (en) |
| CN (1) | CN106661538A (en) |
| AU (1) | AU2015223136A1 (en) |
| BR (1) | BR112016019534A2 (en) |
| CA (1) | CA2940646A1 (en) |
| IL (1) | IL247436A0 (en) |
| MX (1) | MX2016011114A (en) |
| NZ (1) | NZ723750A (en) |
| RU (1) | RU2016137834A (en) |
| SG (1) | SG11201607036XA (en) |
| WO (1) | WO2015130810A2 (en) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9012141B2 (en) | 2000-03-27 | 2015-04-21 | Advaxis, Inc. | Compositions and methods comprising KLK3 of FOLH1 antigen |
| EP2683400A4 (en) | 2011-03-11 | 2014-09-17 | Advaxis | Listeria-based adjuvants |
| SG11201405605VA (en) | 2012-03-12 | 2014-10-30 | Advaxis Inc | SUPPRESSOR CELL FUNCTION INHIBITION FOLLOWING <i>LISTERIA</i> VACCINE TREATMENT |
| WO2015126921A1 (en) | 2014-02-18 | 2015-08-27 | Advaxis, Inc. | Biomarker directed multi-target immunotherapy |
| CA2941405A1 (en) * | 2014-03-05 | 2015-09-11 | Advaxis, Inc. | Methods and compositions for increasing a t-effector cell to regulatory t cell ratio |
| WO2015164121A1 (en) | 2014-04-24 | 2015-10-29 | Advaxis, Inc. | Recombinant listeria vaccine strains and methods of producing the same |
| MA41644A (en) | 2015-03-03 | 2018-01-09 | Advaxis Inc | LISTERIA-BASED COMPOSITIONS INCLUDING A MINIGEN EXPRESSION SYSTEM CODING PEPTIDES, AND METHODS OF USE THEREOF |
| IL259931B2 (en) | 2015-12-16 | 2024-02-01 | Gritstone Bio Inc | Neoantigen identification, manufacture, and use |
| SG10202105561PA (en) | 2016-11-30 | 2021-07-29 | Advaxis Inc | Immunogenic compositions targeting recurrent cancer mutations and methods of use thereof |
| MX2020003100A (en) | 2017-09-19 | 2020-08-20 | Advaxis Inc | COMPOSITIONS AND METHODS FOR LYOPHILIZATION OF BACTERIA OR <i>LISTERIA </i>STRAINS. |
| CN111465989B (en) | 2017-10-10 | 2024-06-25 | 磨石生物公司 | New antigen identification using hot spots |
| CN111630602A (en) | 2017-11-22 | 2020-09-04 | 磨石肿瘤生物技术公司 | Reducing presentation of conjugated epitopes by neoantigens |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6855320B2 (en) * | 2000-03-29 | 2005-02-15 | The Trustees Of The University Of Pennsylvania | Fusion of non-hemolytic, truncated form of listeriolysin O to antigens to enhance immunogenicity |
| US9017660B2 (en) * | 2009-11-11 | 2015-04-28 | Advaxis, Inc. | Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors |
-
2015
- 2015-02-25 CA CA2940646A patent/CA2940646A1/en active Pending
- 2015-02-25 CN CN201580010568.4A patent/CN106661538A/en active Pending
- 2015-02-25 RU RU2016137834A patent/RU2016137834A/en not_active Application Discontinuation
- 2015-02-25 BR BR112016019534A patent/BR112016019534A2/en not_active Application Discontinuation
- 2015-02-25 JP JP2016553897A patent/JP2017507943A/en active Pending
- 2015-02-25 WO PCT/US2015/017559 patent/WO2015130810A2/en active Application Filing
- 2015-02-25 MX MX2016011114A patent/MX2016011114A/en unknown
- 2015-02-25 AU AU2015223136A patent/AU2015223136A1/en not_active Abandoned
- 2015-02-25 KR KR1020247007406A patent/KR20240038103A/en active Search and Examination
- 2015-02-25 KR KR1020167025517A patent/KR20160122829A/en not_active IP Right Cessation
- 2015-02-25 SG SG11201607036XA patent/SG11201607036XA/en unknown
- 2015-02-25 EP EP15755609.3A patent/EP3110942A4/en not_active Withdrawn
- 2015-02-25 NZ NZ723750A patent/NZ723750A/en unknown
-
2016
- 2016-08-23 IL IL247436A patent/IL247436A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2015130810A3 (en) | 2016-01-28 |
| CN106661538A (en) | 2017-05-10 |
| EP3110942A2 (en) | 2017-01-04 |
| EP3110942A4 (en) | 2017-08-30 |
| CA2940646A1 (en) | 2015-09-03 |
| KR20160122829A (en) | 2016-10-24 |
| RU2016137834A (en) | 2018-03-29 |
| KR20240038103A (en) | 2024-03-22 |
| JP2017507943A (en) | 2017-03-23 |
| MX2016011114A (en) | 2017-02-20 |
| BR112016019534A2 (en) | 2017-10-24 |
| IL247436A0 (en) | 2016-11-30 |
| WO2015130810A2 (en) | 2015-09-03 |
| SG11201607036XA (en) | 2016-09-29 |
| AU2015223136A1 (en) | 2016-09-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ723750A (en) | Compositions and methods for the treatment of her2/neu over-expressing tumors | |
| MX2017014908A (en) | Trispecific binding proteins and methods of use. | |
| MX2022015821A (en) | Novel t cell receptors and immune therapy using the same. | |
| MX2019006724A (en) | Novel t cell receptors and immune therapy using the same. | |
| MX2019003298A (en) | Recombinant binding proteins and their use. | |
| MX2019001769A (en) | T cell receptors and immune therapy using the same. | |
| BR112018001572A2 (en) | method for inducing an immune response, antigen, adenovirus, use of antigen and adenovirus, and polynucleotide. | |
| SG10201908086SA (en) | Listeria-based compositions comprising a peptide minigene expression system and methods of use thereof | |
| SG10201900727QA (en) | Personalized immunotherapy against several neuronal and brain tumors | |
| MX2017004729A (en) | Combination therapy for use in cancer therapy. | |
| PH12015502638A1 (en) | Novel immunotherapy against several tumors, such as lung cancer, including nsclc | |
| NZ725079A (en) | Transgene genetic tags and methods of use | |
| PH12019500312A1 (en) | T cell receptors and immune therapy using the same | |
| PH12021551208A1 (en) | Novel immunotherapy against several tumors, such as lung cancer, including nsclc | |
| MA40228A (en) | Recombinant listeria strain expressing heterologous antigen fusion proteins and methods of use thereof | |
| NZ745327A (en) | Whole-cell cancer vaccines and methods for selection thereof | |
| BR112018073221A2 (en) | methods for predicting protein utility or fragments thereof, methods for selecting and / or evaluating specific amino acid modifications, vaccine and vaccine delivery method | |
| EA201790341A1 (en) | ANTI-CK8 ANTIBODIES FOR USE IN TREATMENT OF CANCER | |
| BR112019005513A2 (en) | immunogenic composition, nucleic acid molecule, peptide, and methods for inducing an immune response against fibroblast activation protein and for treating or preventing a tumor-associated pathology. | |
| MX343848B (en) | Her2 dna vaccine as adjunct treatment for cancers in companion animals. | |
| PH12016502008A1 (en) | Novel immunotherapy against several tumors of the blood, such as acute myeloid lukemia (aml) | |
| BR112019004146A2 (en) | immunogenic composition, nucleic acid molecule, peptide, and methods for inducing an immune response against the follicle stimulating hormone receptor and for treating or preventing tumor-associated pathology. | |
| NZ765527A (en) | Antibodies with increased affinity for the epidermal growth factor receptor and fragments derived therefrom | |
| MY195101A (en) | Novel T Cell Receptors and Immune Therapy Using the Same | |
| MY194244A (en) | Novel Immunotherapy Against Several Tumors, Such as Lung Cancer, Including Nsclc |